Table 3 Results of subgroup analysis
Study characteristic | Groups | Studies (nr) | Total sample size | Pooled AUC (95 % CIs) | I2 test | P-value |
|---|---|---|---|---|---|---|
Study setting | Trauma patients | 9, 10, 15 | 787 | 0.83 (0.68, 0.99) | 97 % | 0.0235 |
ICU patients | 4, 5, 12, 16, 17 | 1474 | 0.66 (0.59, 0.73) | 69 % | ||
Age | Mean/Median age 30–40 years | 5, 9, 10, 15 | 1055 | 0.81 (0.69, 0.93) | 97 % | 0.0114 |
Mean/Median age 60–70 years | 4, 8, 12, 16, 17 | 1878 | 0.66 (0.60, 0.71) | 70 % | ||
Intravenous fluids restriction | Restriction | 9, 10 | 356 | 0.91 (0.8, 1.0) | 95 % | 0.0008 |
No restriction | 4, 5, 8, 12, 15, 16, 17 | 2573 | 0.67 (0.62, 0.72) | 68 % | ||
Intravenous fluids restriction and AG measured before treatment initiation | Restriction and AG measurement before hospital treatment initiation | 5, 8, 9, 10 | 1296 | 0.83 (0.73, 0.93) | 98 % | <0.0001 |
No restriction or AG measured after treatment was commenced | 4, 12, 15, 16, 17 | 1633 | 0.63 (0.60, 0.66) | 0 % | ||
Routine use of gelatin-based intravenous fluids in study country | Gelatins not routinely used | 12, 15 | 1091 | 0.62 (0.58, 0.65) | 0 % | 0.3344 |
Gelatins routinely used | 4, 16, 17 | 542 | 0.65 (0.6, 0.7) | 0 % | ||
Outcome measure | Time frame stated e.g. 31-day or 28-day mortality | 4, 9, 10, 12, 16 | 1266 | 0.74 (0.52, 0.96) | 99 % | 0.6518 |
In-hospital mortality | 8, 15, 17 | 1399 | 0.69 (0.64, 0.75) | 44 % | ||
Overall mortality in study population | Below 30 % | 5, 8, 9, 12, 15, 17 | 2613 | 0.74 (0.55, 0.93) | 99 % | 0.8856 |
Above 30 % | 4, 10, 16 | 320 | 0.70 (0.57, 0.84) | 83 % | ||
Date of publication | Before and including 2005 | 4, 5, 8, 9, 15 | 1710 | 0.76 (0.59, 0.94) | 98 % | 0.4325 |
2006 and after | 10, 12, 16, 17 | 1184 | 0.67 (0.58, 0.77) | 87 % |